Valuation: Dr. Reddy's Laboratories Limited

Market Cap 1,024B 10.64B 9.27B 8.56B 7.85B 14.93B 15.2B 102B 40.07B 500B 39.95B 39.08B 1,723B P/E 2027 *
24.4x
P/E 2028 * 19.5x
Enterprise Value 991B 10.3B 8.97B 8.29B 7.6B 14.45B 14.71B 98.74B 38.79B 484B 38.68B 37.83B 1,668B EV / Sales 2027 *
2.79x
EV / Sales 2028 * 2.46x
Free-Float
70.07%
Yield 2027 *
0.63%
Yield 2028 * 0.68%

Last Transcript: Dr. Reddy's Laboratories Limited

Manager TitleAgeSince
Chief Executive Officer 59 2019-06-30
Director of Finance/CFO - 2024-07-31
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2014-05-12
Chairman 65 2013-04-01
Director/Board Member 65 2018-10-24
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 10.8B
+0.35%-6.39%+44.70%+157.34% 1,028B
-2.69%-7.57%+57.52%+54.51% 611B
+0.44%-4.14%+27.46%+79.48% 432B
+0.98%-2.74%+28.13%+21.76% 323B
-0.34%-3.79%+26.52%+43.60% 277B
+1.63%-12.52%+17.86%+21.72% 257B
+3.39%+0.95%-25.43%-37.83% 217B
+0.86%-2.66%+20.63%+57.55% 192B
+1.28%-3.42%+17.49%+70.62% 161B
Average +0.90%-5.24%+23.88%+52.08% 388.7B
Weighted average by Cap. +0.68%-5.52%+32.95%+76.70%

Financials

2027 *2028 *
Net sales 356B 3.7B 3.22B 2.97B 2.73B 5.19B 5.28B 35.45B 13.92B 174B 13.88B 13.58B 599B 395B 4.1B 3.57B 3.3B 3.03B 5.75B 5.86B 39.3B 15.44B 193B 15.4B 15.06B 664B
Net income 42.23B 439M 382M 353M 324M 616M 627M 4.21B 1.65B 20.64B 1.65B 1.61B 71.07B 53.11B 552M 481M 444M 407M 774M 788M 5.29B 2.08B 25.96B 2.07B 2.03B 89.38B
Net Debt -32.67B -339M -296M -273M -251M -476M -485M -3.25B -1.28B -15.96B -1.27B -1.25B -54.97B -54.24B -564M -491M -453M -416M -791M -805M -5.4B -2.12B -26.51B -2.12B -2.07B -91.28B
Logo Dr. Reddy's Laboratories Limited
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Employees
27,527
Trader
Investor
Global
Quality
ESG MSCI
BBB